Azura Ophthalmics is a technology company.
Azura Ophthalmics has raised $36.0M across 2 funding rounds.
Azura Ophthalmics has raised $36.0M in total across 2 funding rounds.
Azura Ophthalmics has raised $36.0M in total across 2 funding rounds.
Azura Ophthalmics's investors include 5AM Ventures, Brandon Capital Partners, Ed Mathers.
Azura Ophthalmics is a clinical-stage biotechnology company developing first-in-class ophthalmic keratolytics to treat underserved ocular surface diseases, primarily meibomian gland dysfunction (MGD), the leading cause of dry eye disease (DED).[1][2][3][4] It builds an innovative portfolio of small molecule compounds, such as AZR-MD-001 (in Phase 3 for MGD and meibomian blepharitis) and others like AZR-MD-004/005/006 (early Phase 1 for dry eye syndromes), delivered via a novel ophthalmic platform to target root causes like gland obstruction, improving signs, symptoms, and patient burden.[2][3][5] Serving millions worldwide with limited treatment options for MGD, DED, blepharitis, and contact lens discomfort, Azura addresses core pathophysiology by combining ophthalmologic and dermatologic approaches.[1][4][5] Growth momentum includes Phase 3 trials for lead candidates and participation in major biopharma conferences, backed by experienced leadership in ocular therapies.[3][4]
Azura Ophthalmics, headquartered in Tel Aviv-Yafo, Israel, with operations in Australia and the United States, emerged from the need to tackle MGD—the primary cause of evaporative DED—where effective pharmaceutical treatments are scarce.[2][4][5] Founded by an experienced management team with a proven track record in developing and commercializing novel devices and pharmaceuticals for ocular surface diseases, the company leverages deep expertise in drug development and ocular pathophysiology.[1][2][4] The idea crystallized around harnessing keratolytics—agents proven in dermatology—to clear lid margin hyperkeratinization, a key MGD driver, marking a pivotal shift toward root-cause therapies rather than symptom management.[1][3] Early traction stems from this novel drug delivery platform and pipeline advancement, supported by investors like Brandon Capital Partners.[4]
Azura rides the surging demand for ocular surface disease treatments amid rising DED prevalence—driven by aging populations, screen time, and contact lens use—affecting hundreds of millions globally with few root-cause solutions.[2][4] Timing is ideal as Phase 3 data for MGD therapies could disrupt a market dominated by palliative drops, filling gaps in evaporative DED and blepharitis where historical approval rates are low.[5] Favorable forces include biotech innovation in targeted small molecules and dermatology crossovers, plus investor interest in ophthalmology pipelines.[3][4] Azura influences the ecosystem by advancing keratolytics as a new therapeutic class, potentially enabling combo therapies and setting standards for MGD management.[1][3]
Azura's Phase 3 readout for AZR-MD-001 could catalyze approvals and partnerships, accelerating commercialization of its keratolytic franchise amid expanding DED markets.[2][5] Trends like personalized ophthalmology, AI-driven trials, and combo drug-device platforms will shape its path, with early-phase assets diversifying into blepharitis and aqueous DED.[5] Influence may grow via global expansion and acquisitions, redefining underserved ocular care. This positions Azura as a paradigm-shifter, fulfilling its mission to deliver transformative therapies from the outset.[1][3]
Azura Ophthalmics has raised $36.0M across 2 funding rounds. Most recently, it raised $20.0M Series C in October 2020.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Oct 1, 2020 | $20.0M Series C | 5AM Ventures, Brandon Capital Partners, Ed Mathers | |
| Oct 1, 2017 | $16.0M Series B | 5AM Ventures, Brandon Capital Partners, Ed Mathers |